PortfoliosLab logoPortfoliosLab logo
KMX vs. AYTU
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

KMX vs. AYTU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CarMax, Inc. (KMX) and Aytu BioPharma, Inc. (AYTU). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, KMX achieves a 22.93% return, which is significantly higher than AYTU's -11.92% return.


KMX

1D
0.74%
1M
17.75%
YTD
22.93%
6M
20.99%
1Y
-27.71%
3Y*
-15.53%
5Y*
-16.21%
10Y*
-0.36%

AYTU

1D
1.78%
1M
-8.40%
YTD
-11.92%
6M
2.23%
1Y
14.50%
3Y*
12.70%
5Y*
-53.73%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

KMX vs. AYTU - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
KMX
CarMax, Inc.
22.93%-52.74%6.54%26.03%-53.24%37.87%7.74%39.76%-2.18%-1.63%
AYTU
Aytu BioPharma, Inc.
-11.92%52.94%-40.14%-24.87%-86.00%-77.42%-38.35%22.41%-98.22%-88.85%

Correlation

The correlation between KMX and AYTU is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.18

Correlation (3Y)
Calculated over the trailing 3-year period

0.14

Correlation (5Y)
Calculated over the trailing 5-year period

0.19

Correlation (All Time)
Calculated using the full available price history since Feb 2, 2017

0.14

Fundamentals

Market Cap

KMX:

$7.01B

AYTU:

$24.07M

EPS

KMX:

$1.66

AYTU:

-$2.91

PS Ratio

KMX:

0.27

AYTU:

0.47

PB Ratio

KMX:

1.19

AYTU:

0.68

Total Revenue (TTM)

KMX:

$25.88B

AYTU:

$56.60M

Gross Profit (TTM)

KMX:

$2.81B

AYTU:

$36.14M

EBITDA (TTM)

KMX:

$768.58M

AYTU:

-$27.34M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

KMX vs. AYTU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KMX
KMX Risk / Return Rank: 2323
Overall Rank
KMX Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
KMX Sortino Ratio Rank: 2222
Sortino Ratio Rank
KMX Omega Ratio Rank: 2121
Omega Ratio Rank
KMX Calmar Ratio Rank: 2525
Calmar Ratio Rank
KMX Martin Ratio Rank: 2828
Martin Ratio Rank

AYTU
AYTU Risk / Return Rank: 5151
Overall Rank
AYTU Sharpe Ratio Rank: 5252
Sharpe Ratio Rank
AYTU Sortino Ratio Rank: 4949
Sortino Ratio Rank
AYTU Omega Ratio Rank: 4949
Omega Ratio Rank
AYTU Calmar Ratio Rank: 5252
Calmar Ratio Rank
AYTU Martin Ratio Rank: 5353
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KMX vs. AYTU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CarMax, Inc. (KMX) and Aytu BioPharma, Inc. (AYTU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


KMXAYTUDifference
Sharpe ratioReturn per unit of total volatility

-0.79

Sortino ratioReturn per unit of downside risk

-1.16

Omega ratioGain probability vs. loss probability

0.94

1.10

-0.16

Calmar ratioReturn relative to maximum drawdown

-0.49

0.41

-0.90

Martin ratioReturn relative to average drawdown

-0.77

0.97

-1.74

KMX vs. AYTU - Sharpe Ratio Comparison

The current KMX Sharpe Ratio is -0.53, which is lower than the AYTU Sharpe Ratio of 0.27. The chart below compares the historical Sharpe Ratios of KMX and AYTU, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


KMXAYTUDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.53

0.27

-0.79

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.37

-0.63

+0.26

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.01

Sharpe Ratio (All Time)

Calculated using the full available price history

0.11

-0.36

+0.47

Drawdowns

KMX vs. AYTU - Drawdown Comparison

The maximum KMX drawdown since its inception was -93.19%, smaller than the maximum AYTU drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for KMX and AYTU.


Loading charts...

Drawdown Indicators


KMXAYTUDifference

Max Drawdown

Largest peak-to-trough decline

-93.19%

-100.00%

+6.81%

Max Drawdown (1Y)

Largest decline over 1 year

-56.85%

-35.47%

-21.38%

Max Drawdown (3Y)

Largest decline over 3 years

-65.38%

-70.24%

+4.86%

Max Drawdown (5Y)

Largest decline over 5 years

-80.06%

-99.12%

+19.06%

Max Drawdown (10Y)

Largest decline over 10 years

-80.06%

Current Drawdown

Current decline from peak

-69.33%

-100.00%

+30.67%

Average Drawdown

Average peak-to-trough decline

-31.74%

-95.15%

+63.41%

Ulcer Index

Depth and duration of drawdowns from previous peaks

36.04%

14.92%

+21.12%

Volatility

KMX vs. AYTU - Volatility Comparison

The current volatility for CarMax, Inc. (KMX) is 11.99%, while Aytu BioPharma, Inc. (AYTU) has a volatility of 14.09%. This indicates that KMX experiences smaller price fluctuations and is considered to be less risky than AYTU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


KMXAYTUDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.99%

14.09%

-2.10%

Volatility (6M)

Calculated over the trailing 6-month period

34.46%

33.39%

+1.07%

Volatility (1Y)

Calculated over the trailing 1-year period

52.71%

55.06%

-2.35%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

44.23%

85.66%

-41.43%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

40.53%

188.20%

-147.67%

Dividends

KMX vs. AYTU - Dividend Comparison

Neither KMX nor AYTU has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

KMX vs. AYTU - Financials Comparison

This section allows you to compare key financial metrics between CarMax, Inc. and Aytu BioPharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
4.52B
12.41M
(KMX) Total Revenue
(AYTU) Total Revenue
Values in USD except per share items

KMX vs. AYTU - Profitability Comparison

The chart below illustrates the profitability comparison between CarMax, Inc. and Aytu BioPharma, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
9.3%
61.2%
Portfolio components
KMX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, CarMax, Inc. reported a gross profit of 420.20M and revenue of 4.52B. Therefore, the gross margin over that period was 9.3%.

AYTU - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a gross profit of 7.60M and revenue of 12.41M. Therefore, the gross margin over that period was 61.2%.

KMX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, CarMax, Inc. reported an operating income of -339.44M and revenue of 4.52B, resulting in an operating margin of -7.5%.

AYTU - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported an operating income of -4.06M and revenue of 12.41M, resulting in an operating margin of -32.8%.

KMX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, CarMax, Inc. reported a net income of -120.68M and revenue of 4.52B, resulting in a net margin of -2.7%.

AYTU - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a net income of -5.62M and revenue of 12.41M, resulting in a net margin of -45.3%.


Frequently Asked Questions


KMX and AYTU have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AYTU has higher volatility (14.09%) compared to KMX (11.99%). In terms of maximum drawdown, KMX dropped -93.19% vs AYTU's -100.00%.

AYTU currently has the higher Sharpe Ratio (0.27 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for KMX and AYTU

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer